roche holding ag - RHHBF

RHHBF

Close Chg Chg %
475.01 -25.16 -5.30%

Closed Market

449.85

-25.16 (5.30%)

Volume: 53.00

Last Updated:

Feb 6, 2026, 3:20 PM EDT

Company Overview: roche holding ag - RHHBF

RHHBF Key Data

Open

$475.01

Day Range

449.85 - 475.01

52 Week Range

288.90 - 475.01

Market Cap

$373.94B

Shares Outstanding

795.62M

Public Float

29.01M

Beta

0.28

Rev. Per Employee

N/A

P/E Ratio

24.38

EPS

N/A

Yield

234.21%

Dividend

$12.76

EX-DIVIDEND DATE

Mar 13, 2026

SHORT INTEREST

N/A

AVERAGE VOLUME

19.36

 

RHHBF Performance

1 Week
 
2.24%
 
1 Month
 
8.56%
 
3 Months
 
32.31%
 
1 Year
 
36.11%
 
5 Years
 
30.39%
 

RHHBF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About roche holding ag - RHHBF

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics, and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

RHHBF At a Glance

Roche Holding AG
Grenzacherstrasse 124
Basel, Basel-Stadt (Basle Town) 4058
Phone 41-61-688-11-11 Revenue 74.07B
Industry Pharmaceuticals: Major Net Income 15.51B
Sector Health Technology 2025 Sales Growth 7.832%
Fiscal Year-end 12 / 2026 Employees N/A
View SEC Filings

RHHBF Valuation

P/E Current 24.38
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 21.716
Price to Sales Ratio 4.587
Price to Book Ratio 7.89
Price to Cash Flow Ratio 15.82
Enterprise Value to EBITDA 13.462
Enterprise Value to Sales 4.958
Total Debt to Enterprise Value 0.114

RHHBF Efficiency

Revenue/Employee N/A
Income Per Employee N/A
Receivables Turnover 4.181
Total Asset Turnover 0.619

RHHBF Liquidity

Current Ratio 1.383
Quick Ratio 1.116
Cash Ratio 0.553

RHHBF Profitability

Gross Margin 73.534
Operating Margin 31.315
Pretax Margin 27.593
Net Margin 20.938
Return on Assets 12.954
Return on Equity 39.91
Return on Total Capital 18.341
Return on Invested Capital 20.771

RHHBF Capital Structure

Total Debt to Total Equity 98.192
Total Debt to Total Capital 49.544
Total Debt to Total Assets 32.959
Long-Term Debt to Equity 84.829
Long-Term Debt to Total Capital 42.801
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Roche Holding Ag - RHHBF

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
66.26B 65.34B 68.69B 74.07B
Sales Growth
-3.54% -1.39% +5.13% +7.83%
Cost of Goods Sold (COGS) incl D&A
19.72B 17.60B 18.20B 19.60B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
4.00B 3.87B 3.89B 4.09B
Depreciation
3.02B 3.07B 3.05B 3.27B
Amortization of Intangibles
982.13M 796.75M 842.54M 813.98M
COGS Growth
-8.48% -10.76% +3.38% +7.73%
Gross Income
46.54B 47.74B 50.49B 54.47B
Gross Income Growth
-1.28% +2.58% +5.78% +7.87%
Gross Profit Margin
+70.23% +73.06% +73.51% +73.53%
2022 2023 2024 2025 5-year trend
SG&A Expense
27.30B 29.31B 29.52B 31.01B
Research & Development
14.71B 14.72B 14.26B 14.69B
Other SG&A
12.59B 14.59B 15.26B 16.33B
SGA Growth
-2.40% +7.35% +0.70% +5.08%
Other Operating Expense
201.03M 233.68M 275.93M 258.88M
Unusual Expense
4.59B 3.55B 7.98B 4.02B
EBIT after Unusual Expense
14.44B 14.65B 12.73B 19.17B
Non Operating Income/Expense
3.33B 1.98B 2.13B 2.69B
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
636.61M 921.38M 1.42B 1.43B
Interest Expense Growth
+70.68% +44.73% +53.80% +0.86%
Gross Interest Expense
636.61M 921.38M 1.42B 1.43B
Interest Capitalized
- - - -
-
Pretax Income
17.14B 15.70B 13.44B 20.44B
Pretax Income Growth
-9.95% -8.38% -14.39% +52.05%
Pretax Margin
+25.87% +24.03% +19.57% +27.59%
Income Tax
2.93B 1.92B 2.96B 3.82B
Income Tax - Current - Domestic
4.66B 3.15B 4.91B 4.06B
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(1.74B) (1.24B) (1.95B) (236.01M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
14.17B 13.75B 10.43B 16.62B
Minority Interest Expense
1.16B 956.99M 1.03B 1.11B
Net Income
13.01B 12.79B 9.40B 15.51B
Net Income Growth
-14.64% -1.62% -26.54% +65.01%
Net Margin Growth
+19.63% +19.58% +13.68% +20.94%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
13.01B 12.79B 9.40B 15.51B
Preferred Dividends
- - - -
-
Net Income Available to Common
13.01B 12.79B 9.40B 15.51B
EPS (Basic)
16.2567 16.0134 11.7924 19.4836
EPS (Basic) Growth
-9.31% -1.50% -26.36% +65.22%
Basic Shares Outstanding
800.00M 799.00M 797.00M 796.00M
EPS (Diluted)
16.2567 15.9138 11.7189 19.3138
EPS (Diluted) Growth
-8.23% -2.11% -26.36% +64.81%
Diluted Shares Outstanding
800.00M 804.00M 802.00M 803.00M
EBITDA
23.03B 22.06B 24.60B 27.28B
EBITDA Growth
-3.09% -4.23% +11.51% +10.91%
EBITDA Margin
+34.76% +33.76% +35.81% +36.83%

Roche Holding Ag in the News